Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 7/20 | 0.33 |
| ▸ | GLI1 | P08151 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13902985 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2D6CCR4GLI1ITGB3 | |
| SCHEMBL13144573 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2D6CCR4GLI1ITGB3 | |
| Hydrochloric Acid SCHEMBL3092057 | 0.98 | CYP3A4 (0.34) | CYP3A4CYP2D6CCR4GLI1ITGB3 | |
| SCHEMBL20096239 | 0.85 | CCR5 (0.39) | CYP3A4CYP2D6CCR4CCR5 | |
| SCHEMBL13817502 | 0.84 | ALDH1A1 (0.39) | CYP3A4CYP2D6CCR4CCR5 | |
| SCHEMBL13903067 | 0.83 | SLC6A4 (0.35) | CYP3A4CYP2D6ITGB3ITGA2BF2R | |
| SCHEMBL13903057 | 0.82 | SLC6A4 (0.36) | CYP3A4CYP2D6ITGB3ITGA2BF2R | |
| SCHEMBL3087322 | 0.82 | CCR4 (0.33) | CCR4ITGB3ITGA2BF2RKCNH2 | |
| SCHEMBL13144577 | 0.81 | SLC6A4 (0.34) | CYP3A4CYP2D6CCR4ITGB3ITGA2B | |
| SCHEMBL13144576 | 0.81 | SLC6A4 (0.34) | CYP3A4CYP2D6CCR4ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790884-B2 | Acylaminopiperidine compound | ASTELLAS PHARMA INC. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20090131666-A1 | ACYLAMINOPIPERIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-2000469-A9 | ACYLAMINOPIPERIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2000469-A2 | ACYLAMINOPIPERIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131666-A1 | ACYLAMINOPIPERIDINE COMPOUND | CCR4, CCR1, CCR3 | CYP3A4 1928/4885CYP2D6 2690/4885CCR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.